ERBB3 and neoplasm: In a clinical trial where patients with HER2+ breast cancer were treated with the HER2 TKI lapatinib, there was significant upregulation of HER3 protein without inhibition of S473-AKT in tumor core biopsies obtained at 2 weeks of treatment [25, 26].